Publication date: Available online 12 October 2026 Source: Clinical Lymphoma Myeloma and Leukemia Author(s): Won-Seog Kim, Huilai Zhang, Dai Maruyama, Astrid Pavlovsky, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam J. Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Jason Westin, Lihua E. Budde
Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040024?dgcid=rss_sd_all
Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040024?dgcid=rss_sd_all
“Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article41310,
title = {Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040024?dgcid=rss_sd_all}
}